Biota Told By U.S. To Suspend Development Of Two Flu Drugs
This article was originally published in PharmAsia News
Executive Summary
Biota Pharmaceuticals said it has been ordered by the U.S. health department to suspend work on two influenza drug contracts while it considers a recently completed review of their contract.